<DOC>
	<DOCNO>NCT01037101</DOCNO>
	<brief_summary>The study determine effect D-Cycloserine ( DCS ) fear reduction patient diagnose phobia height ( acrophobia ) undergo one session three hour virtual reality exposure therapy ( VRET ) vivo exposure therapy ( IVET ) .</brief_summary>
	<brief_title>D-Cycloserine-Enhancer One-Session Treatment Phobia Heights</brief_title>
	<detailed_description>The impact D-Cycloserine Virtual Reality Exposure Therapy ( VRET ) In Vivo Exposure Therapy ( IVET ) phobia height ( acrophobia ) test use randomize , double-blind , placebo-controlled trial . Eighty participant randomly assign one four treatment condition : one-session VRET ( 3 hour ) 50 mg D-Cycloserine ( VR-OST + DCS , N1=20 ) ; one-session VRET ( 3 hour ) placebo ( VR-OST + Pl , N2=20 ) ; one-session IVET ( 3 hour ) placebo ( IV + Pl , N3=20 ) ; one-session IVET ( 3 hour ) 50 mg D-Cycloserine , ( IV + DCS , N4=20 ) . For twenty participant ( 5 group ) treatment delay three week additional assessment conduct comprise Wait List ( WL ) control group . Behavioral , cognitive physiological change acrophobia assessed pre-treatment , post-waitlist , post-treatment 3 month follow-up .</detailed_description>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>Age 18 65 year Men woman Diagnosis acrophobia base clinical interview ( ADISIV ) Must sign inform consent document complete explanation study document understand purpose study , procedure undertake , possible benefit , potential risk , willing participate . A lifetime history bipolar disorder , schizophrenia , psychosis , delusional disorder ; organic brain syndrome , cognitive dysfunction could interfere capacity engage therapy ; A history substance alcohol dependence ( nicotine ) last 6 month otherwise unable commit refrain alcohol use period study participation . Patients significant suicidal ideation enact suicidal behavior within 6 month prior intake exclude study participation refer appropriate service . Patients must concurrent anxiolytic beta blocker stable dose antidepressant medication least 3 week prior initiation randomize treatment . Patients receive medication might interfere study medication ( medication might lower seizure threshold : meperidine antibiotic high dosage : penicillin , cephalosporin , amphotericin imipenem ) , Patients current past history seizure Pregnant woman , lactate woman , woman childbearing potential use medically accept effective method contraception abstinence Patients history renal insufficiency ( creatinine clearance le 60 mL/min ) liver insufficiency Any concurrent psychotherapy initiate within 3 month baseline , ongoing psychotherapy duration specifically target phobias Patients unable understand study procedure participate inform consent process . Other serious medical illness ( e.g. , cardiovascular , liver , kidney , respiratory , endocrine , neurologic , bloodrelated disease ) , Inability tolerate wear Virtual Reality Head Mounted Display , If patient refuse study medication Any allergic reaction DCycloserine history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>acrophobia</keyword>
	<keyword>virtual reality</keyword>
	<keyword>exposure therapy</keyword>
	<keyword>In Vivo Exposure Therapy plus D-Cycloserine</keyword>
	<keyword>In Vivo Exposure Therapy plus Placebo</keyword>
	<keyword>Virtual Reality Exposure Therapy plus D-Cycloserine</keyword>
	<keyword>Virtual Reality Exposure Therapy plus Placebo</keyword>
	<keyword>Wait-List</keyword>
</DOC>